Skip to main content

Advertisement

SpringerLink
Log in

The potential of peptide immunotherapy in allergy and asthma

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Allergic conditions contribute significantly to the burden of chronic disease in the industrialized world. Current treatments offer varying degrees of palliation. The sole proven disease-modifying strategy, specific or whole-allergen immunotherapy, is limited because of the associated risk of systemic adverse effects, such as anaphylaxis. Short, linear allergen-derived peptides, corresponding to T cell epitopes, offer the possibility of a safer approach as they are capable of inducing allergen-specific hyporesponsiveness without cross-linking mast cell-bound IgE. This review evaluates the scientific basis of peptide immunotherapy and clinical experience in allergy up to the present time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Varney VA, Gaga M, Frew AJ, et al.: Usefulness of immunotherapy in patients with severe summer hayfever uncontrolled by antiallergic drugs. Br Med J 1991, 302:265–269.

    Article  CAS  Google Scholar 

  2. Varney VA, Edwards J, Tabbah K, et al.: Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997, 27:860–867.

    Article  PubMed  CAS  Google Scholar 

  3. Durham SR, Walker SM, Varga E-M, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468–475.

    Article  PubMed  CAS  Google Scholar 

  4. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558–562.

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organization. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998, 53(suppl):1–42.

    Article  Google Scholar 

  6. Hamid Q, Azzawi M, Ying S, et al.: Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991, 87:1541–1546.

    PubMed  CAS  Google Scholar 

  7. Robinson DS, Hamid Q, Ying S, et al.: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298–304.

    Article  PubMed  CAS  Google Scholar 

  8. Ying S, Durham SR, Corrigan CJ, et al.: Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995, 12:477–487.

    PubMed  CAS  Google Scholar 

  9. Bentley AM, Meng Q, Robinson DS, et al.: Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993, 8:35–42.

    PubMed  CAS  Google Scholar 

  10. Robinson D, Hamid Q, Bentley A, et al.: Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993, 92:313–324.

    Article  PubMed  CAS  Google Scholar 

  11. Huang SK, Xiao HQ, Kleine-Tebbe J, et al.: IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995, 155:2688–2694.

    PubMed  CAS  Google Scholar 

  12. Robinson DS, Ying S, Bentley AM, et al.: Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol 1993, 92:397–403.

    Article  PubMed  CAS  Google Scholar 

  13. Kay AB: Allergy and allergic diseases. First of two parts. N Engl J Med 2001, 344:30–37.

    Article  PubMed  CAS  Google Scholar 

  14. Karin N, Binah O, Grabie N, et al.: Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease. J Immunol 1998, 160:5188–5194.

    PubMed  CAS  Google Scholar 

  15. Warren KG, Catz I, Wucherpfennig KW: Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 1997, 152:31–38.

    Article  PubMed  CAS  Google Scholar 

  16. Lamb JR, Skidmore BJ, Green N, et al.: Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza haemagglutinin. J Exp Med 1983, 157:1434–1447.

    Article  PubMed  CAS  Google Scholar 

  17. Essery G, Feldmann M, Lamb JR: Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology 1988, 64:413–417.

    PubMed  CAS  Google Scholar 

  18. O’Hehir RE, Lamb JR: Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins. Proc Natl Acad Sci U S A 1990, 87:8884–8888.

    Article  PubMed  CAS  Google Scholar 

  19. O’Hehir RE, Aguilar BA, Schmidt TJ, et al.: Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T-cell clones. Clin Exp Allergy 1991, 21:209–215.

    Article  PubMed  CAS  Google Scholar 

  20. O’Hehir RE, Yssel H, Verma S, et al.: Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol 1991, 3:819–826.

    Article  PubMed  CAS  Google Scholar 

  21. Briner T, Kuo M, Keating K, et al.: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. Proc Natl Acad Sci U S A 1993, 90:7608–7612.

    Article  PubMed  CAS  Google Scholar 

  22. Hoyne G, O’Hehir RE, Wraith D, et al.: Inhibition of T-cell and antibody responses to house dust mite allergen by inhalation of the dominant T-cell epitope in naive and sensitised mice. J Exp Med 1993, 178:1783–1788.

    Article  PubMed  CAS  Google Scholar 

  23. Hoyne GF, Askonas BA, Hetzel C, et al.: Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int Immunol 1996, 8:335–342.

    Article  PubMed  CAS  Google Scholar 

  24. Astori M, von Garnier C, Kettner A, et al.: Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol 2000, 165:3497–3505.

    PubMed  CAS  Google Scholar 

  25. Custovic A, Fletcher A, Pickering CAC, et al.: Domestic allergens in public places. III. House dust mite, cat, dog, and cockroach allergens in British hospitals. Clin Exp Allergy 1998, 28:53–59.

    Article  PubMed  CAS  Google Scholar 

  26. Counsell CM, Bond JF, Ohman JL, et al.: Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. J Allergy Clin Immunol 1996, 98:884–894.

    Article  PubMed  CAS  Google Scholar 

  27. Norman PS, Ohman JL, Long AA, et al.: Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996, 154:1623–1628.

    PubMed  CAS  Google Scholar 

  28. Marcotte GV, Braun CM, Norman PS, et al.: Effects of peptide therapy on ex-vivo T-cell responses. J Allergy Clin Immunol 1998, 101:506–513.

    Article  PubMed  CAS  Google Scholar 

  29. Pène J, Desroches A, Paradis L, et al.: Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T-cells of patients allergic to cats. J Allergy Clin Immunol 1998, 102:571–578.

    Article  PubMed  Google Scholar 

  30. Simons F, Imada M, Li Y, et al.: Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996, 8:1937–1945.

    Article  PubMed  CAS  Google Scholar 

  31. Maguire P, Nicodemus C, Robinson D, et al.: The safety and efficacy of ALLERVAX CAT in cat-allergic patients. Clin Immunol 1999, 93:222–231.

    Article  PubMed  CAS  Google Scholar 

  32. Muller U, Akdis CA, Fricker M, et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998, 101:747–754. First description of allergen-derived peptide induction of T cell hyporesponsiveness in bee venom-allergic patients.

    Article  PubMed  CAS  Google Scholar 

  33. Akdis CA, Blesken T, Akdis M, et al.: Role of interleukin-10 in specific immunotherapy. J Clin Invest 1998, 102:98–106. Finding that the induction of allergen-specific anergic state in peripheral T cells with SIT is associated with increased IL-10 production.

    PubMed  CAS  Google Scholar 

  34. Haselden BM, Kay AB, Larché M: IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999, 189:1885–1894. Demonstration of MHC-restricted recognition of allergenderived peptides by T cells from allergic asthmatic subjects developing isolated LARs following intradermal peptide injection.

    Article  PubMed  CAS  Google Scholar 

  35. Oldfield WLG, Kay AB, Larché M: Allergen-derived T-cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001, 167:1734–1739. Demonstration of the induction of antigen-specific T cell hyporesponsiveness and reduced late-phase cutaneous response to whole allergen in cat allergic asthmatics following a single dose of allergen-derived peptides.

    PubMed  CAS  Google Scholar 

  36. Alexander C, Oldfield WLG, Shirley KE, et al.: A dosing protocol of allergen-derived T-cell peptide epitopes for the treatment of allergic disease [abstract]. J Allergy Clin Immunol 2001, 107:716.

    Google Scholar 

  37. Oldfield WLG, Shirley KE, Larché M, Kay AB: A double-blind, placebo-controlled study of short peptides derived from Fel d 1 in cat-allergic subjects [abstract]. J Allergy Clin Immunol 2001, 107:711.

    Google Scholar 

  38. Powrie F, Carlino J, Leach MW, et al.: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996, 183:2669–2674.

    Article  PubMed  CAS  Google Scholar 

  39. Weiner HL, Inobe J, Kuchroo V, Chen Y: Induction and characterisation of TGFb secreting Th3 cells. FASEB J 1996, 10:A1444.

    Google Scholar 

  40. Akdis CA, Akdis M, Blesken T, et al.: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996, 98:1676–1683.

    Article  PubMed  CAS  Google Scholar 

  41. Levings MK, Sangregorio R, Roncarolo MG: Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001, 193:1295–1302. Demonstration of the ability to isolate and propagate human regulatory T cells using exogenous IL-2.

    Article  PubMed  CAS  Google Scholar 

  42. Hoyne GF, Jarnicki AG, Thomas WR, Lamb JR: Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: a role for intramolecular epitope suppression. Int Immunol 1997, 9:1165–1173.

    Article  PubMed  CAS  Google Scholar 

  43. Cobbold S, Waldmann H: Infectious tolerance. Curr Opin Immunol 1998, 10:518–524.

    Article  PubMed  CAS  Google Scholar 

  44. Hoyne GF, Le Roux I, Corsin-Jimenez M, et al.: Serrate1- induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol 2000, 12:177–185. Demonstration of the induction of antigen-specific hyporesponsiveness through the Notch cell signaling pathway.

    Article  PubMed  CAS  Google Scholar 

  45. Hoyne GF, Dallman MJ, Lamb JR: T-cell regulation of peripheral tolerance and immunity: the potential role for Notch signalling. Immunology 2000, 100:281–288.

    Article  PubMed  CAS  Google Scholar 

  46. Chen Y, Inobe J, Marks R, et al.: Peripheral deletion of antigenreactive T cells in oral tolerance. Nature 1995, 376:177–180.

    Article  PubMed  CAS  Google Scholar 

  47. Rolland J, O’Hehir R: Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr Opin Immunol 1998, 10:640–645.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Allergy and Clinical Immunology, Faculty of Medicine, Imperial College, National Heart and Lung Institute, Dovehouse Street, SW3 6LY, London, UK

    F. Runa Ali MRCP, A. Barry Kay MD, PhD & Mark Larché PhD

Authors
  1. F. Runa Ali MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Barry Kay MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Larché PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ali, F.R., Kay, A.B. & Larché, M. The potential of peptide immunotherapy in allergy and asthma. Curr Allergy Asthma Rep 2, 151–158 (2002). https://doi.org/10.1007/s11882-002-0010-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-002-0010-5

Keywords

Search

Navigation